Pharma and Biotech Financial Outlook


In general, the last several years have been fruitful for both the pharmaceutical and biotechnology industries. Most crucially, the two segments of the industry have entered a golden age in terms of the growth in the number of new pharmaceuticals that have been approved and are in development.


New methods of research and the development of new treatment alternatives, such as biologics, stem cells, and medications for susceptible cancer patients, are responsible for many of these breakthroughs.


Due in part to these encouraging developments, public valuations of pharma and biotech businesses as well as M&A requests rose up to August/September of this year. Recent public assessments have changed due to the unfavourable publicity surrounding drug price.


 

    Related Conference of Pharma and Biotech Financial Outlook

    February 01-02, 2024

    37th World Congress on Pharmacology

    Dubai, UAE
    February 22-23, 2024

    34th Annual European Pharma Congress

    Zurich, Switzerland
    April 04-05, 2024

    17th European Biosimilars Congress

    Madrid, Spain
    April 11-12, 2024

    5th Annual Congress on Antibiotics and Bacterial Infections

    Amsterdam, Netherlands
    May 09-10, 2024

    4th Global Summit on Pharmaceutical Research

    Barcelona, Spain
    May 16-17, 2024

    18th World Drug Delivery Summit

    Rome, Italy
    May 30-31, 2024

    9th Pharmaceutical Chemistry Conference

    Paris, France
    September 11-12, 2024

    9th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    September 25-26, 2024

    4th World Congress on Rare Diseases & Orphan Drugs

    Paris, France

    Pharma and Biotech Financial Outlook Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in